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SUMMARY
Heart rate, a major determinant of angina in coronary
disease, is also an important predictor of cardiovascular
mortality. Lowering heart rate is therefore one of the
most important therapeutic approaches in the treatment
of stable angina pectoris. To date, b-blockers and some
calcium-channel antagonists reduce heart rate, but their use
may be limited by adverse reactions or contraindications.
Heart rate is determined by spontaneous electrical pace-
maker activity in the sinoatrial node controlled by the If
current. Ivabradine is the first specific heart rate-lowering
agent that has completed clinical development for stable
angina pectoris. It is selective for the If current, lowering
heart rate at concentrations that do not affect other cardiac
ionic currents. Specific heart-rate lowering with ivabradine
reduces myocardial oxygen demand, simultaneously
improving oxygen supply. Ivabradine has no negative ino-
tropic or lusitropic effects, preserving ventricular contrac-
tility, and does not change any major electrophysiological
parameters unrelated to heart rate. Randomised clinical
studies in patients with stable angina show that ivabradine
effectively reduces heart rate, improves exercise capacity
and reduces the number of angina attacks. It has superior
anti-anginal and anti-ischaemic activity to placebo and
is non-inferior to atenolol and amlodipine. Ivabradine
therefore offers a valuable approach to lowering heart rate
exclusively and provides an attractive alternative to con-
ventional treatment for a wide range of patients with
confirmed stable angina.
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INTRODUCTION
The most prevalent cardiovascular disease in Western society
is atherosclerotic coronary artery obstruction, of which angina
pectoris is the primary symptom. Angina is a symptom of
myocardial ischaemia, which occurs when insufficient oxygen
is supplied to the heart muscle. Heart rate is a primary
determinant of myocardial oxygen demand and may also
affect myocardial perfusion. Lowering heart rate increases
the duration of diastole relative to cardiac cycle length, allow-
ing more time for effective left ventricular (LV) filling and
coronary perfusion. Therefore, lowering the heart rate may
improve both the aspects of myocardial oxygen balance.
Heart rate may also be involved in the progression of
atherosclerosis in patients with coronary heart disease (1).
High heart rate is associated with coronary plaque disruption,
independent of blood pressure, possibly as a result of increased
haemodynamic stress (2). Taken together, these effects predict
that lowering heart rate may improve myocardial efficiency.
Thereisconsiderableevidencethatsurvivalisinverselyrelated
to heart rate, both for the general population and in several
specific disease states (3–18), including angina (19). Thus, the
modulation of heart rate is important in patients with angina.
ROLE OF THE IF CURRENT
In the normal, non-diseased state, heart rate is controlled by
the sinoatrial node, the origin of cardiac pacemaker activity.
Sinoatrial myocytes, the pacemaker cells in the heart, have the
unique capacity to spontaneously generate slow diastolic
depolarisation, driving the membrane voltage away from the
hyperpolarised level reached at the completion of one action
potential towards the threshold level for initiating a sub-
sequent action potential. The rhythmic action potentials
generated in this way propagate through the conducting
systems of the heart and trigger myocardial contraction.
Pacemaker activity involves interplay between several ionic
currents that influence spontaneous diastolic depolarisation of
the sinoatrial node, including the If current (20). The ‘f’
denotes ‘funny’, so called because it had unusual properties
compared with other current systems known at the time of its
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DRUG FOCUS doi: 10.1111/j.1368-5031.2006.00817.xdiscovery. The If current is carried by both sodium and
potassium ions across the sarcolemma; it is inward at voltages
in the diastolic range, is activated on hyperpolarisation
(within the diastolic range of voltages regularly observed
in cardiac pacemaker tissue) (21) and is characterised by
unusually low single-channel conductance and slow activation
kinetics. The If current is directly activated by intracellular
cyclic adenosine monophosphate (cAMP), not linked to
cAMP-dependent phosphorylation activity (22) and is carried
by the hyperpolarisation-activated cyclic nucleotide-gated
family of ion channels (23). These form the naturally occur-
ring If channels in cardiac pacemaker cells and the related Ih
channels in certain neuronal structures.
The If and Ih channels open and close in response to both
ambient voltage and local intracellular cAMP concentrations.
Adrenergic agonists activate adenylate cyclase, increasing local
cAMP concentrations and thus increasing cAMP binding
to the If channel (24). Conversely, cholinergic transmitters
decrease local cAMP concentrations by inhibiting adenylate
cyclase, thereby decreasing cAMP binding to the If channel.
An If channel bound to cAMP is more likely to open, increas-
ing the rate of slow diastolic depolarisation, whereas an
unbound channel is more likely to remain closed, lowering
the heart rate (25).
LOWERING THE HEART RATE IN ANGINA
Lowering heart rate reduces cardiac work, thereby diminishing
myocardial oxygen demand. This mechanism is the primary
basis for the anti-ischaemic and anti-anginal effects of heart
rate-lowering drugs. Heart-rate lowering might also increase
coronary blood flow and, thus, myocardial oxygen supply,
mitigating ischaemia by increasing diastolic perfusion time,
during which coronary flow proceeds against relatively low
resistance (26,27). This effect is most pronounced in the highly
vulnerable subendocardium, where contraction-induced resis-
tance is greatest. In theory, the disruption of atherosclerotic
plaques is partly due to mechanical perturbation of the plaque
by foreshortening and twisting of large epicardial arteries dur-
ing systole, which is diminished by heart-rate lowering (2).
Heart-rate modulation is part of standard angina-
prevention strategies. However, under current treatments,
almost two-thirds of patients continue to experience an
average of two angina episodes per week despite simultaneous
use of multiple anti-anginal drugs (28).
CURRENT THERAPEUTIC OPTIONS
Although b-adrenergic blocking drugs lower heart rate and
prevent angina in patients with coronary artery disease,
b-blockade may be associated with adverse events, including
hypotension, psychological depression, erectile dysfunction
and worsening of intrinsic atrioventricular node disease (29),
obstructive pulmonary diseases (30), diabetes mellitus (31),
hyperlipidaemia (32) and intermittent claudication and
related symptoms in patients with occlusive peripheral arterial
disease (33), a relatively common concomitant of coronary
artery disease. In addition, ‘rebound’ effects, sometimes fatal,
have been reported when short-acting b-blockers are stopped
abruptly (34).
In addition, b-blockers and certain heart rate-lowering
calcium antagonists have negative inotropic effects and may
be inappropriate in patients with heart failure or with
atrioventricular node dysfunction. Calcium antagonists can
also cause constipation or peripheral oedema (35).
Long-acting nitrates, which do not lower heart rate but
cause reflex cardio-acceleration (36), can produce headaches
or light-headedness. Continual administration of these agents
can lead to pharmacological tolerance to therapeutic effects
(37) and can be associated with rebound angina and vasocon-
striction when stopped.
In the light of these complications, alternative approaches
to angina prevention have been sought, including the low-
ering of heart rate through novel mechanisms.
THE IF CURRENT AS A PHARMACOLOGICAL
TARGET
More than three decades ago, the search began for pure heart
rate-lowering agents that would prevent angina without the
adverse effects of b-blockers. The discovery of the If current
and If channels offered a possible approach to developing
pure heart rate-lowering agents. Ivabradine has a considerable
selectivity for If channel blockade (38), which allows the
administration of doses that cause relatively pronounced If
current inhibition and substantial heart-rate lowering.
Currently, ivabradine is the only If current inhibitor in the
late-stage clinical development.
Ivabradine reduces the firing rate of the pacemaker cells in
the sinoatrial node without affecting the duration of the
action potential (20,39), whilst acting at concentrations
that have no effect on other ionic currents, making ivabra-
dine a selective If inhibitor (40). Ivabradine blocks If
channels in a concentration-dependent manner by entering
the channel pore from the intracellular side (40,41).
Blockade is only possible when the If channel is open, and
the magnitude of If inhibition is directly related to the
frequency of channel opening. Unlike other heart rate-
lowering mechanisms, direct If blockade depends on the
current driving force, as block dramatically increases
across the voltage interval, and on sodium concentration in
the surrounding milieu (41). Thus, ivabradine would be
expected to be most effective at higher heart rates, where
its clinical usefulness would also be greatest.
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Several experimental studies in animals, including dogs and
pigs, have clarified the different beneficial effects that may be
associated with pure heart-rate lowering with ivabradine.
Although ivabradine and the b-blocker propranolol reduced
both tachycardia during exercise and ST-segment shift to the
same extent, ivabradine, unlike propranolol, does not reduce
LV contractility and preserves systolic shortening fraction in
ischaemic regions to a greater degree than propranolol (42).
Furthermore, the recovery of contractility in ischaemic LV
contractile dysfunction is significantly more rapid with ivab-
radine than with another b-blocker, atenolol (43,44). Heart-
rate lowering with ivabradine also dose-dependently increases
diastolic time and reduces myocardial oxygen consumption,
giving a linear relationship between heart rate and oxygen
consumption (27). In contrast, the negative inotropic action
of atenolol leads to a prolonged ejection time and, conse-
quently, a smaller increase in diastolic time for the same
reduction in heart rate compared with ivabradine (26).
Ivabradine, unlike atenolol, does not depress the physiological
exercise-induced acceleration of LV relaxation, so ivabradine
does not show the negative lusitropic effects associated with
b-blockade (45).
These beneficial effects of ivabradine compared with
b-blockers may be because, unlike ivabradine, b-blockers
reduce If activation by decreasing sympathetic activity and
cAMP formation, thereby lowering heart rate. Although the
negative inotropic effects of b-blockers contribute directly to
the diminution of myocardial oxygen consumption, they can
also limit the increases in coronary flow otherwise associated
with heart-rate lowering (26,27). Also, myocardial relaxation
occurs more slowly with b-blockade than with If current
inhibition, which also minimises the impact of b-blockers
on flow (45).
Heart-rate lowering with If inhibition, unlike that with
b-blockade, results in increased stroke volume, supporting
cardiac output and coronary flow (46). If inhibition may
improve LV function and ventricular remodelling (47).
CLINICAL STUDIES OF IVABRADINE IN THE
PREVENTION OF ANGINA
Preclinical and clinical studies show that therapeutic doses of
ivabradine are likely to be well tolerated in clinical use.
Ivabradine at these doses has no negative inotropic effects in
healthy volunteers (48) or in patients with LV dysfunction
(49), causes no peripheral vasodilation and has no effect on
the cardiac conduction system (50). Furthermore, no rebound
effects with drug cessation or pharmacological tolerance with
long-term use have been observed following ivabradine treat-
ment (51). Because of their mechanism of action, If inhibitors
are contraindicated in patients with intrinsic sinoatrial node
disease (e.g. sick sinus syndrome); such patients were excluded
from ivabradine trials.
The efficacy of ivabradine monotherapy in patients with
stable angina has been evaluated in two published large-scale
clinical studies. The anti-anginal, anti-ischaemic effect of
ivabradine, alone and in combination with other drugs, and
its tolerability have been assessed in a clinical programme
involving more than 5000 patients. Ivabradine 5 mg and
7.5 mg twice daily (bid) are the licensed dosages for the
treatment of stable angina.
Ivabradine Monotherapy
A randomised, placebo-controlled, double-blind, multicentre,
multinational study in 360 patients with stable angina for at
least 3 months and documented coronary artery disease eval-
uated ivabradine in a short dose-ranging phase and in longer-
term use (52). Initially, participants received either placebo or
ivabradine orally twice daily for 2 weeks. The primary efficacy
criteria were time to 1-mm ST-segment depression (a measure
of ischaemia) and time to limiting angina during exercise
tolerance testing (ETT). Patients recorded angina attacks
and nitroglycerin consumption in diaries.
After 2 weeks of treatment, resting heart rate was signifi-
cantly slower with ivabradine compared with placebo at both
peak and trough drug activities, and this reduction increased
significantly with increasing dose ( 4.5 and  9.5 bpm at 2.5
and 5.0 mg, respectively) (Figure 1). Heart rate rose slightly,
but not significantly, on placebo. Maximal heart rate at peak
exercise was lowered to the same extent as resting heart rate.
The reduction in heart rate during exercise was associated
with a significant increase in time to 1-mm ST-segment
depression during ETT in a dose-dependent manner, and
there was a statistical trend to improvement in time to limit-
ing angina after just 2 weeks. Analysis indicated that time to
limiting angina increased compared with placebo although
not reaching statistical significance (Figure 2). A similar
increase was seen in time to 1-mm ST-segment depression,
although this reached significance at ivabradine doses of 5 mg
(Figure 3). The frequency of angina attacks and consumption
of short-acting nitrates tended to fall with ivabradine use,
which reached significance by the end of the 2–3-month
open-label phase.
Blood pressure was little affected by the drug, with no
hypotension at peak or trough drug effect with any dose.
The only reported adverse reactions were dosage-related visual
symptoms which were reported in less than 2% of patients
with 5 mg orally twice daily. Such effects were generally
transient, always reversible and very seldom severe enough
to cause patients to voluntarily stop the drug.
The results of the International Trial on the Treatment of
angina with Ivabradine vs. Atenolol (INITIATIVE) have just
been published (53). This randomised, double-blind study
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patients with stable angina pectoris and documented coronary
artery disease. Patients received either ivabradine 5 mg twice
daily for 4 weeks increased to 7.5 mg twice daily for a further
3 months, or atenolol 50 mg once daily for 4 weeks increased
to 100 mg once daily for a further 3 months. At 4 months,
total exercise duration on a treadmill ETT at trough drug
activity increased by 86.8 s with ivabradine 7.5 mg and
78.8 s with atenolol 100 mg (Figure 4). At trough drug
activity, ivabradine 7.5 mg was non-inferior to atenolol for
all primary and secondary analyses including time to limiting
angina, time to angina onset and time to 1-mm ST-segment
depression at month 4 (p < 0.0001). Ivabradine was non-
inferior to atenolol at peak drug activity at month 1 for all
parameters. By month 4, non-inferiority of ivabradine 7.5 mg
to atenolol was retained for all parameters except time to
1-mm ST-segment depression. Visual symptoms occurred at
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Figure 2 Effect of ivabradine on time to angina sufficient to limit
continued bicycle exercise among protocol-compliant patients with
coronary artery disease. Measurements were obtained after 2 weeks
of double-blind randomised therapy. A dose–response relationship is
apparent. Adapted from (52)
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Figure 3 Changes in time to 1-mm ST-segment depression at
trough (A) and peak (B) drug activity. *p < 0.05 vs. placebo.
bid ¼ twice daily. Adapted from (52)
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Figure 1 Changes in heart rate in the different treatment groups
during the double-blind, dose-ranging phase at rest (A) and at peak
exercise (B). *p < 0.05 vs. placebo in pairwise comparisons. bid ¼
twice daily. Adapted from (52)
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indicate that by lowering heart rate, ivabradine is at least as
effective as atenolol in patients with stable angina pectoris.
Extension of the analysis in patients aged over 65 years
confirmed that the efficacy of ivabradine is maintained
in older patients (54).
Preliminary data have been presented from a trial involving
1195 patients (55). In this double-blind, randomised study,
patients received either amlodipine or ivabradine for 3
months. Ivabradine 7.5 mg bid significantly increased total
exercise duration by 27.6 s. In addition, ivabradine also
improved both angina, as measured by time to limiting
angina and time to angina onset, and ischaemia, as measured
by time to 1-mm ST-segment depression. Formal statistical
testing indicated that ivabradine was non-inferior to
amlodipine in preventing angina (p < 0.0001). Ivabradine
significantly decreased the number of angina attacks by
two-thirds and reduced use of short-acting nitrates.
Ivabradine Combination Therapy
In a 12-month, double-blind study, 386 patients receiving
nitrates or calcium blockers for the treatment of angina were
randomised to receive ivabradine 5.0 mg or 7.5 mg twice
daily concomitant to their existing therapy (56). Ivabradine
reduced heart rate by 10 and 12 bpm, respectively, for 5.0
and 7.5 mg doses. Moreover, the number of angina attacks
was significantly reduced from baseline to month 12 in
patients receiving ivabradine.
Tolerability Studies
Ivabradine reduces heart rate without any observed effects on
myocardial contractility and does not alter the cardiac con-
duction system (49,50). In one study, 14 patients received a
single intravenous administration of ivabradine (0.2 mg/kg).
Resting heart rate was lower by approximately 14 bpm, but
no major electrophysiological parameters other than those
related to the heart rate were altered (57). As expected, the
QT interval was prolonged by 37.5 s. However, when QT
was corrected for heart rate (QTc), there was no QTc
prolongation. Ivabradine did not modify the PR and QRS
intervals or the conductivity and refractoriness of the atrium,
atrioventricular node, His-Purkinje system and ventricles.
In a randomised, placebo-controlled study in 44 patients
with LV dysfunction, a single intravenous infusion of ivabra-
dine 0.2–0.3 mg/kg lowered the resting heart rate by more
than 17%, whilst preserving fractional shortening (49).
Although ivabradine is selective for If channels, it can also
interact with the structurally similar retinal Ih channel. Data
from clinical trials demonstrated that visual symptoms were
reported in less that 2% of patients receiving the 5 mg bid
dosage of ivabradine and that there were few withdrawals
(<1%). Furthermore, ivabradine was not associated with
any alteration of ocular structures or permanent visual dis-
orders. In addition, most visual effects reported were mild and
only occurred as occasional brief episodes, often associated
with abrupt changes in light intensity. These episodes had
minimal impact on patients’ daily activities with no deleter-
ious effects on their quality of life (54).
CONCLUSION
‘Pure’ heart-rate lowering via If inhibition is clinically feasible
and can effectively prevent angina with acceptable tolerability.
Ivabradine effectively prevents angina and concomitantly
reduces ischaemia. Ivabradine is currently the only agent
shown to clinically lower heart rate with no negative inotrop-
ism or effects on conduction and contractility.
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